These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31484543)

  • 1. N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
    Obata Y; Hara Y; Shiina I; Murata T; Tasaki Y; Suzuki K; Ito K; Tsugawa S; Yamawaki K; Takahashi T; Okamoto K; Nishida T; Abe R
    Cell Commun Signal; 2019 Sep; 17(1):114. PubMed ID: 31484543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
    Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
    Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
    [No Abstract]   [Full Text] [Related]  

  • 3. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
    Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
    Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
    Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
    Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors.
    Obata Y; Horikawa K; Takahashi T; Akieda Y; Tsujimoto M; Fletcher JA; Esumi H; Nishida T; Abe R
    Oncogene; 2017 Jun; 36(26):3661-3672. PubMed ID: 28192400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic Kit signalling on the Golgi is suppressed by blocking secretory trafficking with M-COPA in gastrointestinal stromal tumours.
    Obata Y; Horikawa K; Shiina I; Takahashi T; Murata T; Tasaki Y; Suzuki K; Yonekura K; Esumi H; Nishida T; Abe R
    Cancer Lett; 2018 Feb; 415():1-10. PubMed ID: 29196126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
    Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
    Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
    Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells.
    Hara Y; Obata Y; Horikawa K; Tasaki Y; Suzuki K; Murata T; Shiina I; Abe R
    PLoS One; 2017; 12(4):e0175514. PubMed ID: 28403213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
    Larizza L; Magnani I; Beghini A
    Leuk Lymphoma; 2005 Feb; 46(2):247-55. PubMed ID: 15621809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid rafts are required for Kit survival and proliferation signals.
    Jahn T; Leifheit E; Gooch S; Sindhu S; Weinberg K
    Blood; 2007 Sep; 110(6):1739-47. PubMed ID: 17554062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B; Ding K; Pan J
    Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
    Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
    Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
    Yang Y; Huang Q; Lu Y; Li X; Huang S
    J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.
    Xiang Z; Kreisel F; Cain J; Colson A; Tomasson MH
    Mol Cell Biol; 2007 Jan; 27(1):267-82. PubMed ID: 17060458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.
    Le Gall M; Crépin R; Neiveyans M; Auclair C; Fan Y; Zhou Y; Marks JD; Pèlegrin A; Poul MA
    Mol Cancer Ther; 2015 Nov; 14(11):2595-605. PubMed ID: 26358753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia.
    Murray HC; Miller K; Brzozowski JS; Kahl RGS; Smith ND; Humphrey SJ; Dun MD; Verrills NM
    Mol Cell Proteomics; 2023 Mar; 22(3):100503. PubMed ID: 36682716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
    Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.